Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum Toxin in Palatopharyngeal Muscle for OSA
NCT07399782Phase 2Not yet recruiting
- Sponsor
- Hospital Felício Rocho
- Start
- Apr 2026
- Primary completion
- Sep 2026
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label, single-arm trial of botulinum toxin type A in obstructive sleep apnea (OSA), sponsored by Hospital Felício Rocho. Primary endpoint: Apnea-Hypopnea Index at 12 months. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
obstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT07399782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07399782.